Summary of the interim report
The "Company" or "Xintela" refers to Xintela AB (publ), corporate registration number 556780-3480.
THE GROUP
Second quarter 2024
Income amounted to TSEK 4 (0).
Loss before tax totalled TSEK 10,400 (loss: 18,401).
Loss per share was SEK 0.02 (loss: 0.06).
First half year 2024
Income amounted to TSEK 303 (0).
Loss before tax totalled TSEK 21,773 (loss: 34,244).
Loss per share was SEK 0.04 (loss: 0.11).
THE PARENT COMPANY
Second quarter 2024
Income amounted to TSEK 4 (0).
Loss before tax totalled TSEK 8,565 (loss: 11,151).
Loss per share was SEK 0.02 (loss: 0.04).
First half year 2024
Income amounted to TSEK 303 (0).
Loss before tax totalled TSEK 18,254 (loss: 21,553).
Loss per share was SEK 0.03 (loss: 0.07).
At June 30, 2024, the equity/assets ratio was 44 % (17).
Significant events in the second quarter of 2024
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses. (May 23, 2024)
Significant events after the end of the period
Xintela extends clinical study with XSTEM on knee osteoarthritis patients. (August 23, 2024)
Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients. (August 29, 2024)
The complete report is available for download below and on the company's website www.xintela.se/en/report-archive.
Contacts
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se
About Xintela
Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin a10ß1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin a10ß1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser is Carnegie Investment Bank AB (publ).
